Heron Therapeutics
HRTX
190 hedge funds and large institutions have $1.33B invested in Heron Therapeutics in 2020 Q2 according to their latest regulatory filings, with 37 funds opening new positions, 69 increasing their positions, 53 reducing their positions, and 38 closing their positions.
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
30% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 53
22% more capital invested
Capital invested by funds: $1.1B → $1.33B (+$237M)
3% less first-time investments, than exits
New positions opened: 37 | Existing positions closed: 38
2% less funds holding
Funds holding: 193 → 190 (-3)
4.92% less ownership
Funds ownership: 102.69% → 97.77% (-4.9%)
19% less call options, than puts
Call options by funds: $5.02M | Put options by funds: $6.17M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$24.6M |
| 2 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$12.1M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$11.3M |
| 4 |
BlackRock
New York
|
+$11M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$9.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$40.9M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$18.1M |
| 3 |
Fidelity International
Hamilton,
Bermuda
|
-$17.1M |
| 4 |
Renaissance Technologies
New York
|
-$13.3M |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$11.9M |
HRTX Hedge Fund Activity: Q2 2020 in Review
190 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q2 2020, worth a combined $1.33B — up 22% from $1.1B a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of HRTX and 37 opened new positions — a net loss of 1 holder — while 53 trimmed existing stakes and 69 added.
The largest buyer was Invesco, adding an estimated $24.6M. The largest seller was Janus Henderson Group, cutting an estimated $40.9M.
- 190 institutional investors held Heron Therapeutics (HRTX) as of Q2 2020, down from 193 in Q1 2020.
- Funds reported $1.33B of Heron Therapeutics stock for Q2 2020, up 22% quarter-over-quarter.
- 37 funds opened new Heron Therapeutics positions in Q2 2020 and 38 closed out, a net change of -1 holder.
- The largest Heron Therapeutics buyer in Q2 2020 was Invesco, an estimated $24.6M added.
- The largest Heron Therapeutics seller in Q2 2020 was Janus Henderson Group, an estimated $40.9M sold.
Based on aggregated 13F filings for Q2 2020.